The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: A 2-year experience report.

Autor: Crommelynck S; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France. Electronic address: samuel.crommelynck@ansm.sante.fr., Grandvuillemin A; Regional Pharmacovigilance Centre of Burgundy, University Hospital Dijon Bourgogne, 21000 Dijon, France., Ferard C; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France., Mounier C; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France., Gault N; French National Agency for Medicines and Health Products Safety, ANSM, General Direction for Operations, PRAC representative, 93200 Saint-Denis, France., Pierron E; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France., Jacquot B; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France., Vaillant T; French National Agency for Medicines and Health Products Safety, ANSM, General Direction for Operations, PRAC representative, 93200 Saint-Denis, France., Chatelet IPD; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Santé Publique France, Infectious Diseases, 94410 Saint-Maurice, France., Jacquet A; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France., Salvo F; Regional Pharmacovigilance Centre of Bordeaux, DROM, University Hospital of Bordeaux, 33000 Bordeaux, France; UMR 1219 Pharmacoepidemiology Team, Bordeaux Population Health Research Centre, Inserm, University of Bordeaux, 33000 Bordeaux, France., Alt M; Regional Pharmacovigilance Centre, University Hospital of Strasbourg, 67091 Strasbourg, France., Bagheri H; Department of Medical and ClinicalPharmacology, Centre of Pharmacovigilance, Pharmacoepidemiology and Informations on Medications, Inserm UMR 1027, University Hospital and Faculty of Medicine, 31000 Toulouse, France., Micallef J; Department of Clinical Pharmacology and Pharmacovigilance, Regional Pharmacovigilance Centre of Marseille, AP-HM, 13000 Marseille, France., Pariente A; Regional Pharmacovigilance Centre of Bordeaux, DROM, University Hospital of Bordeaux, 33000 Bordeaux, France., Gautier S; Departement of Clinical Pharmacology, University Hospital, Regional Pharmacovigilance Centre of Lille, 59000 Lille, France., Valnet-Rabier MB; Regional Pharmacovigilance Centre of Franche-Comté, University Hospital of Besançon, 25000 Besançon, France., Atzenhoffer M; University Hospital Department of Pharmacotoxicology, Regional Pharmacovigilance Centre, Civil Hospices of Lyon (HCL), 69003 Lyon, France., Lepelley M; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Regional Pharmacovigilance Centre, University Hospital of Grenoble-Alpes, 38000 Grenoble, France., Cottin J; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; University Hospital Department of Pharmacotoxicology, Regional Pharmacovigilance Centre, Civil Hospices of Lyon (HCL), 69003 Lyon, France., Lacroix I; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Department of Medical and ClinicalPharmacology, Centre of Pharmacovigilance, Pharmacoepidemiology and Informations on Medications, Inserm UMR 1027, University Hospital and Faculty of Medicine, 31000 Toulouse, France., Gras V; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Pharmacovigilance Centre, Department of Clinical Pharmacology, Amiens Picardie University Medical Centre, 80054 Amiens, France., Massy N; Regional Pharmacovigilance Centre, Clinical Pharmacology Department, Rouen University Hospital, 76031 Rouen, France., Dhanani A; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France., Vella P; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France., Shaim Y; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France., Baril L; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Santé Publique France, Infectious Diseases, 94410 Saint-Maurice, France., Jonville-Béra AP; French National Agency for Medicines and Health Products (ANSM), Direction for Medical Drugs Department, Department of Infections and Emerging Disease, 93200 Saint-Denis, France; Departement of Pharmacosurveillance, University Hospital, Regional Pharmacovigilance Centre Val-de-Loire, 37000 Tours, France., Benkebil M; French National Agency for Medicines and Health Products Safety, ANSM, Direction for Surveillance, 93200 Saint-Denis, France.

Publikováno v: Therapie [Therapie] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.

The human VGLUT3-pT8I mutation elicits uneven striatal DA signaling, food or drug maladaptive consumption in male mice.

Autor: Favier M; Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, H4H 1R3, Canada. mathieu.favier@mail.mcgill.ca., Martin Garcia E; Laboratory of Neuropharmacology-Neurophar, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Departament de Psicobiologia i Metodologia de les Ciències de la Salut, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193, Barcelona, Spain., Icick R; Département de Psychiatrie et de Médecine Addictologique, DMU Neurosciences, APHP.Nord, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, F-75010, France.; INSERM U1144, 'Therapeutic optimization in neuropsychopharmacology', Paris, F-75006, France.; Université Paris Cité, Inserm UMR-S1144, Paris, F-75006, France.; Neurobiologie Intégrative des Systèmes Cholinergiques, Département de Neurosciences, Institut Pasteur, Paris, F-75015, France., de Almeida C; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Jehl J; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France.; Brain Plasticity Unit, CNRS UMR 8249, ESPCI Paris, PSL Research University, 75005, Paris, France., Desplanque M; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Zimmermann J; Neurocure NWFZ, Charite Universitaetsmedizin, Institut für Neurophysiologie, Charitéplatz 1, 10117, Berlin, Germany., Henrion A; Fondation FondaMental, Créteil, France.; Université Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, F-94010, Créteil, France., Mansouri-Guilani N; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Mounier C; Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, H4H 1R3, Canada., Ribeiro S; Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, H4H 1R3, Canada., Henderson F; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Geoffroy A; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Mella S; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Poirel O; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Bernard V; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Fabre V; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., Li Y; State Key Laboratory of Membrane Biology, Peking University School of Life Sciences, Beijing, China., Rosenmund C; Neurocure NWFZ, Charite Universitaetsmedizin, Institut für Neurophysiologie, Charitéplatz 1, 10117, Berlin, Germany., Jamain S; Fondation FondaMental, Créteil, France.; Université Paris Est Créteil, INSERM, IMRB, Translational Neuropsychiatry, F-94010, Créteil, France., Vorspan F; Département de Psychiatrie et de Médecine Addictologique, DMU Neurosciences, APHP.Nord, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, F-75010, France.; INSERM U1144, 'Therapeutic optimization in neuropsychopharmacology', Paris, F-75006, France.; Université Paris Cité, Inserm UMR-S1144, Paris, F-75006, France., Mourot A; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France.; Brain Plasticity Unit, CNRS UMR 8249, ESPCI Paris, PSL Research University, 75005, Paris, France., Duriez P; GHU Paris Psychiatrie et Neurosciences (CMME, Hospital Sainte-Anne), Institute of Psychiatry and Neuroscience of Paris (INSERM UMR1266), Paris, France., Pinhas L; PHLIP Mental Health and Painless Medicine clinic, Toronto, Canada., Maldonado R; Laboratory of Neuropharmacology-Neurophar, Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain.; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Departament de Psicobiologia i Metodologia de les Ciències de la Salut, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193, Barcelona, Spain., Pietrancosta N; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France.; Sorbonne Université, École normale supérieure, PSL University, CNRS, Laboratoire des Biomolécules, LBM, 75005, Paris, France.; LCBPT, Université Paris Descartes, Sorbonne Paris Cité, UMR 8601, CNRS, Paris, 75006, France., Daumas S; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France., El Mestikawy S; Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, QC, H4H 1R3, Canada. salah.elmestikawy@mcgill.ca.; Sorbonne Université, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), 75005, Paris, France. salah.elmestikawy@mcgill.ca.

Publikováno v: Nature communications [Nat Commun] 2024 Jul 07; Vol. 15 (1), pp. 5691. Date of Electronic Publication: 2024 Jul 07.

The upgrade of the cold neutron three-axis spectrometer IN12 at the ILL

Autor: Schmalzl, K., Schmidt, W., Raymond, S., Feilbach, H., Mounier, C., Vettard, B., Brückel, T.

Publikováno v: In Nuclear Inst. and Methods in Physics Research, A 21 May 2016 819:89-98

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS

Autor: Houot, R., Le Gouill, S., Ojeda Uribe, M., Mounier, C., Courby, S., Dartigeas, C., Bouabdallah, K., Alexis Vigier, M., Moles, M.P., Tournilhac, O., Arakelyan, N., Rodon, P., El Yamani, A., Sutton, L., Fornecker, L., Assouline, D., Harousseau, J.L., Maisonneuve, H., Caulet-Maugendre, S., Gressin, R. ^*

Publikováno v: In Annals of Oncology June 2012 23(6):1555-1561

Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.

Autor: Cartron G; Department of Hematology, UMR CNRS 5535, University Hospital, Montpellier, France., Bachy E; Department of Hematology, University Hospital, Lyon, France., Tilly H; Department of Hematology, U1245, Henri Becquerel Institute, Rouen, France., Daguindau N; Departement of Hematology, Annecy-Genevois Hospital Centre, Annecy, France., Pica GM; Departement of Hematology, Hospital Centre, Chambery, France., Bijou F; Departement of Hematology, Bergonié Institute, Bordeaux, France., Mounier C; Departement of Hematology, Oncology and Hematology Institute, Sainte-Etienne, France., Clavert A; Departement of Hematology, University Hospital, Angers, France., Damaj GL; Departement of Hematology, University Hospital, Caen, France., Slama B; Departement of Hematology, Hospital Centre, Avignon, France., Casasnovas O; Departement of Hematology, University Hospital, Dijon, France., Houot R; Departement of Hematology, University Hospital, Rennes, France., Bouabdallah K; Departement of Hematology, University Hospital, Bordeaux, France., Sibon D; Departement of Hematology, Necker Hospital, APHP, Paris, France., Fitoussi O; Departement of Hematology, Polyclinic Bordeaux Nord, Bordeaux, France., Morineau N; Departement of Hematology, Hospital Centre, La Roche-sur-Yon, France., Herbaux C; Department of Hematology, UMR CNRS 5535, University Hospital, Montpellier, France., Gastinne T; Departement of Hematology, University Hospital, Nantes, France., Fornecker LM; Departement of Hematology, University Hospital, Strasbourg, France., Haioun C; Departement of Hematology, Lymphoma Malignancies Unit, Henri Mondor Hospital, APHP, Créteil, France., Launay V; Departement of Hematology, Hospital Centre, Saint-Brieuc, France., Araujo C; Departement of Hematology, Hospital Centre, Bayonne, France., Benbrahim O; Departement of Hematology, Hospital Centre, Orléans, France., Sanhes L; Departement of Hematology, Hospital Centre, Perpignan, France., Gressin R; Departement of Hematology, University Hospital, Grenoble, France., Gonzalez H; Departement of Hematology, Hospital Centre, Pontoise, France., Morschhauser F; Department of Hematology, ULR 7365 GRITA, University Hospital, Lille, France., Ternant D; UMR7292, University François-Rabelais, Tours, France., Xerri L; Department of Biopathology, Paoli-Calmettes Institue, Marseille, France., Tarte K; UMR1236, Department of Immunology, Rennes I University, Rennes, France., Pranger D; Department of Haematology, Hospital Centre, Charleroi, Belgium.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jul 01; Vol. 41 (19), pp. 3523-3533. Date of Electronic Publication: 2023 Apr 18.